NMTR - NMTR STOCK NEWS

9 Meters Biopharma (NASDAQ:NMTR) announced a significant milestone, receiving feedback from the FDA on its pre-IND meeting for NM-136, a treatment for obesity. This positive interaction provides essential insights and regulatory clarity, guiding the company toward its IND submission planned for the second half of 2023, contingent on financial readiness. NM-136 is a first-in-class monoclonal antibody targeting glucose-dependent insulinotropic polypeptide (GIP), with promising preclinical results in weight loss without affecting food intake. The approach addresses the obesity epidemic affecting over 40% of the U.S. population.

9 Meters Biopharma (NASDAQ:NMTR) provided an update on its milestones and financial results for the fourth quarter and full year ended December 31, 2022. The company is focused on advancing its Phase 3 vurolenatide program for short bowel syndrome (SBS) and has emphasized the need for a clinical development partner. Financially, 9 Meters reported a net loss of $11.9 million for Q4 and $43.8 million for the full year. The company’s cash position declined from $39.4 million to $29.7 million within three months. A recent $5 million equity offering aims to extend its cash runway through Q3 2023.

9 Meters Biopharma (NASDAQ:NMTR) has closed a registered direct offering of 3,125,000 common stock shares and 6,250,000 warrants at a combined price of $1.60 per share, raising approximately $5 million. The proceeds will finance the clinical development of vurolenatide for short bowel syndrome, support other pipeline programs, and cover working capital needs. The exercise price of the warrants is $1.35, valid for three and a half years post-issuance. H.C. Wainwright & Co. facilitated the offering. The company acknowledges the need for future capital to sustain operations amid ongoing market conditions.

9 Meters Biopharma (NASDAQ:NMTR) announced a registered direct offering to sell 3,125,000 shares of common stock and 6,250,000 warrants at a combined price of $1.60 per share. The exercise price for the warrants is set at $1.35, expiring in three and a half years. This offering aims to raise $5 million to support clinical development for vurolenatide in treating short bowel syndrome and to fund other pipeline programs. The transaction is expected to close around March 15, 2023.

RALEIGH, NC / ACCESSWIRE / March 7, 2023 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) announced that CEO John Temperato will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 3:20 PM ET. The presentation will focus on the company's pipeline, particularly the Phase 3 development of vurolenatide for short bowel syndrome. A replay of the presentation will be available for 90 days post-event. 9 Meters specializes in innovative treatments for rare digestive diseases and is also developing NM-136 for obesity disorders. For more details, follow the company on Twitter, LinkedIn, and Facebook.

9 Meters Biopharma (NASDAQ:NMTR) announced that its CEO John Temperato will present at the BIO CEO & Investor Conference on February 6, 2023, at 10:00 AM ET in New York City. The presentation will focus on the company's pipeline, specifically the vurolenatide, a GLP-1 agonist in Phase 3 development for short bowel syndrome, along with upcoming milestones. 9 Meters is committed to advancing treatments for rare digestive diseases, including other near clinical-stage assets like NM-136 for obesity disorders. For further details, visit their social media channels or the official press release.

9 Meters Biopharma announces the Phase 3 trial of vurolenatide for treating short bowel syndrome (SBS). The trial, called VIBRANT 2, is set to begin by year-end and will involve up to 50 sites across North America and Europe. The study aims to include around 105 participants and assess key endpoints related to parenteral support volume and stool output. Successful results may lead to a future New Drug Application for vurolenatide, targeting an unmet need in SBS treatment for patients without parenteral support.

9 Meters Biopharma has announced an ongoing collaboration with Gustave Roussy, focusing on the effects of intestinal microbiome on cancer treatment responses. This partnership utilizes NM-102, a microbiome modulator, which has shown improved survival rates in preclinical models when combined with immune checkpoint inhibitors (ICIs). An IND-enabling pathway for NM-102 aims for indication selection in 2023. The collaboration seeks to advance microbiota-centered interventions in cancer therapy, underlining the significance of gut health in enhancing ICI efficacy.